SCHEMBL29908940

SCHEMBL29908940

CN(C(=O)OC(C)(C)C)c1ccc(NC(=O)CCCCCCC(=O)OC(C)(C)C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 14/20 0.56
HDAC3 O15379 11/20 0.51
HDAC1 Q13547 11/20 0.51
HDAC2 Q92769 11/20 0.51
HDAC6 Q9UBN7 11/20 0.51
HDAC11 Q96DB2 10/20 0.51
HDAC5 Q9UQL6 9/20 0.51
HDAC10 Q969S8 9/20 0.51
HDAC7 Q8WUI4 8/20 0.51
HDAC4 P56524 7/20 0.51
HDAC9 Q9UKV0 7/20 0.51
L3MBTL1 Q9Y468 1/20 0.45
NCOR2 Q9Y618 2/20 0.44
HSP90AA1 P07900 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
NFKB1 P19838 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29908945 0.90 HDAC8 (0.51) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL29908969 0.83 HDAC8 (0.57) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL24881075 0.82 HDAC8 (0.63) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL31522340 0.82 HDAC8 (0.67) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL1744913 0.80 HDAC8 (0.61) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL557990 0.79 HDAC8 (0.60) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL29908950 0.78 HDAC8 (0.51) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL24880999 0.78 HDAC8 (0.61) HDAC8HDAC3HDAC1HDAC2HDAC6
Sebacic Acid SCHEMBL3905690 0.77 HDAC8 (0.57) HDAC8HDAC3HDAC1HDAC2HDAC6
SCHEMBL30207564 0.76 HPGD (0.57) HDAC8HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569563-B2 Selective HDAC6 degraders and methods of use thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-03-10 US disclosed
US-20230011665-A1 SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-12 US disclosed
EP-4054607-A1 SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2022-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230011665-A1 SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF HDAC6, HDAC1, HDAC11 HDAC8 8/4885HDAC3 4/4885HDAC1 2/4885
US-12569563-B2 Selective HDAC6 degraders and methods of use thereof HDAC6, HDAC1, HDAC11 HDAC8 9/4885HDAC3 4/4885HDAC1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.